Acceptance of COVID-19 Vaccination Across India: How Concerned are the Health Care Workers?
Authors/Creators
- 1. MBBS, DA, DNB (Anaesthesiology), IDCCM, EDAIC, EDIC, Consultant & Head of department, Critical Care Medicine, SMBT IMS & RC, Nandi Hills, Dhamangaon, Igatpuri, Nashik
- 2. MBBS, MD (Anaesthesiology), Consultant & Head of Department, Anaesthesiology, Ashoka Medicover Hospital, Nashik
- 3. MBBS, MD, DNB (Anaesthesiology), FNB (Critical Care), Jr Consultant, Internal Medicine & Critical Care, Sahyadri Superspeciality Hospital, Nashik
- 4. Second year MBBS student, SMBT IMS & RC, Nandi hills, Dhamangaon, Igatpuri, Nashik
- 5. MBBS (Intern), Smt Kashibai Navale Medical College, Narhe, Pune
- 6. MBBS, MD FISCCM, PGDHHM, FICCM, Professor & Head, Department of Anaesthesiology, Critical Care & Pain Division of Critical Care Medicine, Tata Memorial Hospital, Homi Bhabha National Institute, Dr Ernest Borges Road, Parel Mumbai
Description
Background and objectives: In COVID19 vaccination drive, Healthcare workers (HCWs) were first to receive the vaccine. But their concern about the safety of the vaccine prompted us to conducted this survey. Methods: A questionnaire-based online survey was conducted to know post-vaccination symptoms in vaccinated and reasons of refusal in non-vaccinated HCWs. Results: Among 2036 eligible respondents 1589 were vaccinated. In vaccinated group 665 experienced at least one post-vaccination symptom while remaining had no symptoms. Most commonly experienced post-vaccination symptom was pain at injection site (31.8%) and myalgia (31.7%) and were mild to moderate. Age showed inverse relationship with the post vaccination reactogenicity (p<0.001) whereas gender and brand of vaccine showed no significant association. Respondents with comorbidities experienced significantly less symptoms (p<0.001) whereas those with prior COVID19 infection showed significantly higher incidence of post-vaccination symptoms (p<0.046). Among non-vaccinated 447(22.0%) respondents, lack of availability was the major reason cited (29.7%). Interpretation and conclusion: Apart from few mild to moderate, transient, self-limiting symptoms, no HCW reported any major post-vaccination symptom, including elderly with comorbidities, assuring safety of vaccine. We can encourage and appeal general public to participate in vaccination drive without any apprehension, and strengthen the fight against COVID19 pandemic.
Abstract (English)
Background and objectives: In COVID19 vaccination drive, Healthcare workers (HCWs) were first to receive the vaccine. But their concern about the safety of the vaccine prompted us to conducted this survey. Methods: A questionnaire-based online survey was conducted to know post-vaccination symptoms in vaccinated and reasons of refusal in non-vaccinated HCWs. Results: Among 2036 eligible respondents 1589 were vaccinated. In vaccinated group 665 experienced at least one post-vaccination symptom while remaining had no symptoms. Most commonly experienced post-vaccination symptom was pain at injection site (31.8%) and myalgia (31.7%) and were mild to moderate. Age showed inverse relationship with the post vaccination reactogenicity (p<0.001) whereas gender and brand of vaccine showed no significant association. Respondents with comorbidities experienced significantly less symptoms (p<0.001) whereas those with prior COVID19 infection showed significantly higher incidence of post-vaccination symptoms (p<0.046). Among non-vaccinated 447(22.0%) respondents, lack of availability was the major reason cited (29.7%). Interpretation and conclusion: Apart from few mild to moderate, transient, self-limiting symptoms, no HCW reported any major post-vaccination symptom, including elderly with comorbidities, assuring safety of vaccine. We can encourage and appeal general public to participate in vaccination drive without any apprehension, and strengthen the fight against COVID19 pandemic.
Files
IJPCR,Vol14,Issue1,Article70.pdf
Files
(161.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3b9de9f696a823f98172ee197cc2afc7
|
161.8 kB | Preview Download |
Additional details
Dates
- Accepted
-
2021-12-28
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue1,Article70.pdf
- Development Status
- Active
References
- 1. COVID-19 vaccines. Accessed January 27, 2021. https://www.who.int/ emergencies/diseases/novelcoronavirus-2019/ covid-19-vaccines (https://www.who.int/emergencies/dise ases/novel-coronavirus-2019/covid-19- vaccines). 2. WHO target product profiles for COVID-19 vaccines. April 9, 2020. https://www.who.int/publications/m/item/who- target-product-profiles-forcovid-19-vaccines (accessed Nov 8, 2020). 3. Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19. June, 2020. https://www.fda.gov /regulatory-information/search-fdaguidance- documents/developmentand-licensure-vaccines-prevent-covid19. 4. Fact sheet for vaccine recipient COVISHIELDTM ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant). https://www.seruminstitute.com/pdf/co vishield_fact_sheet.pdf. 2021; 5. Voysey M, Clemens SAC, Madhi SA et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. 6. Fact sheet for vaccine recipients and caregivers. COVAXIN ® vaccine SARS-CoV-2 Vaccine by Bharat Biotech. https://www.bharatbiotech. com/images/covaxin/covaxin-factsheet.pdf. 7. Covid-19: Indian health officials defend approval of vaccine. BMJ2021;372: n52.pmid: 33414156. 8. Ella R, Vadrevu KM, Jogdand H, etal. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. LancetInfectDis 2021;21:S1473-3099(20)30942-7. doi: 10.1016/S1473-3099(20)30942-7. pmid: 33485468. 9. Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety Wednesday, https://worldhealthorganization.cmail1 9.com/t/ViewEmail/d/BF096066B984 974F2540EF23F30FEDED/B596817A 142A3C504E9AB52EF5D51DA2. 10. Maheshi N Ramasamy, Angela M Minassian, Katie J Ewer, Amy L Flaxman, Pedro M Folegatti, Daniel R Owens, Merryn Voysey, Parvinder K Aley, Brian Angus, Gavin Babbage, Sandra Belij-Rammerstorfer, Lisa Berry, Sagida Bibi, Mustapha Bittaye KC et al. P. Articles Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults ( COV002 ): a single-blind , randomised , controlled , phase 2 / 3 trial. Lancet. 2020;396:1979–93. 11. Jayadevan R, Shenoy R, TS A. Survey of symptoms following COVID-19 vaccination in India. medRxiv [Internet]. 2021 Jan 1;2021.02.08. 21251366. Available from: http://medrxiv.org/content/early/2021/ 02/12/2021.02.08.21251366.abstract 12. Nichenametla P. Bhopal volunteer's death unrelated to Covaxin, says Bharat Biotech. Deccan Herald. 10 Jan 2021. https://www.deccanherald.com/nationa l/bhopal-volunteers-death-unrelatedto-covaxin-says-bharat-biotech937199.html. 13. Omjasvin MD. Alleging side-effects from Covishield vaccine trials, Chennai-based volunteer seeks Rs 5 crore compensation. New Indian Express. 29 Nov 2020. https://www.newindianexpress.com/cities/chennai/2020/nov/29/ alleging-side-effects-from-covishield 14. https://www.cdc.gov/vaccines/covid19/info-by-product/clinicalconsiderations.html.